Find Clinical Trial

Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, controlled study. – CL2-33138-PO-C-RISP-160P-SCHIZOPHRENIA


← Back
Study Phase

Phase 2

Therapeutic Area

Neuropsychiatric Diseases

IndicationSchizophrenia
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S033138

Active Substance CodeS033138
Protocol CodeCL2-33138-007
EudraCT Code2005-000016-27


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility